Abstract
Hsp90 is a molecular chaperone with important roles in regulating the function of several proteins with potential pathogenic activity. Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases. Molecules that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function. A number of these inhibitors from several chemical classes are now known, and some are already in clinical trials. This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clinically viable drugs for the treatment of cancer. Their potential towards neurodegenerative diseases will also be touched upon.
Keywords: Heat shock protein 90, purine, cancer, neurodegeneration
Current Topics in Medicinal Chemistry
Title: Purine-Scaffold Hsp90 Inhibitors
Volume: 9 Issue: 15
Author(s): Tony Taldone and Gabriela Chiosis
Affiliation:
Keywords: Heat shock protein 90, purine, cancer, neurodegeneration
Abstract: Hsp90 is a molecular chaperone with important roles in regulating the function of several proteins with potential pathogenic activity. Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases. Molecules that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function. A number of these inhibitors from several chemical classes are now known, and some are already in clinical trials. This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clinically viable drugs for the treatment of cancer. Their potential towards neurodegenerative diseases will also be touched upon.
Export Options
About this article
Cite this article as:
Taldone Tony and Chiosis Gabriela, Purine-Scaffold Hsp90 Inhibitors, Current Topics in Medicinal Chemistry 2009; 9 (15) . https://dx.doi.org/10.2174/156802609789895737
DOI https://dx.doi.org/10.2174/156802609789895737 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Herbal Nano Formulations: Patent and Regulatory Overview
Applied Clinical Research, Clinical Trials and Regulatory Affairs Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy
Current Pharmacogenomics and Personalized Medicine Thinking Outside the ‘Block’: Alternative Polymer Compositions for Micellar Drug Delivery
Current Topics in Medicinal Chemistry Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Novel Approaches for Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Synthesis, Molecular Docking Study and in vitro Anticancer Activity of Tetrazole Linked Benzochromene Derivatives
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Meet Our Editorial Board Member
Letters in Drug Design & Discovery Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets